Trials / Terminated
TerminatedNCT00686894
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse. This study will assess the ability of the Power Doppler Ultrasonography (PDUS) to be a reliable marker of enthesitis response and relapse in subjects treated with infliximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | PDUS | PDUS scored for each enthesitis every 2 weeks for 24 weeks. |
| DRUG | Infliximab | * 5 mg/kg * IV * Frequency : weeks 0,2,6 |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-05-30
- Last updated
- 2017-03-13
- Results posted
- 2010-03-05
Source: ClinicalTrials.gov record NCT00686894. Inclusion in this directory is not an endorsement.